{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T19:39:18Z","timestamp":1793475558406,"version":"4.5.0"},"reference-count":15,"publisher":"BMJ","issue":"7","license":[{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"unspecified","delay-in-days":19,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2026,7,3]]},"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Programmed death receptor 1 (PD-1) blockade produces high response rates in resectable and locally advanced cutaneous squamous cell carcinoma (CSCC), but how many doses are needed and whether surgery or radiation after immunotherapy (consolidation) adds benefit in deep responders (patients with substantial clinical responses) remain unclear. Observational inference is challenging because treatment decisions are response-guided, doses accumulate over time, and treatment selection depends on patient characteristics that also affect outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective cohort study of 189 patients with resectable, borderline-resectable, locally advanced, or limited metastatic CSCC treated with immune checkpoint inhibitors as part of management (2019\u20132025). We summarized responses, treatment discontinuation patterns, and time-to-event outcomes. To evaluate dose-response relationships, we fit Bayesian regression models adjusting for prespecified baseline confounders. Directed acyclic graphs were used to formalize causal assumptions and identify minimally sufficient adjustment sets. For event-free survival (EFS), we used a prespecified landmark analysis among patients receiving \u22652 doses to reduce guarantee-time bias.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Objective response occurred in 119\/189 (63%), including 52\/189 (27.5%) complete responses. Nearly half of patients received \u22642 doses (92\/189, 48.7%). Among 50 complete responders managed without surgery, 1 recurrence was observed over a median follow-up of 25.4 months. Dose-response models showed a consistent but modest positive association between additional doses and response: in a linear model, each additional dose was associated with ~1.09\u2009fold higher odds of response (posterior probability &gt;95%). Flexible threshold models suggested early concentration of benefit, strongest at 2 versus 1\u2009dose (93.6% posterior probability of benefit), with persistent uncertainty in effect magnitude (66% probability of \u22656 percentage-point absolute increase). In the EFS landmark modeling cohort (n=177), receipt of \u22653 versus 2 doses showed a 93% posterior probability of reduced event risk, but the 89% credible interval spanned the null (HR 0.61\u20131.01), indicating substantial uncertainty regarding incremental downstream benefit.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In real-world CSCC, durable disease control frequently occurred after limited immunotherapy exposure, and clinical responders often did well without routine surgical consolidation. Although additional doses may modestly improve outcomes, observed gains appear concentrated early with uncertain incremental value beyond two doses. These patterns support conceptualizing treatment as frontline immunotherapy with response-guided subsequent treatment rather than fixed-duration neoadjuvant therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2026-015029","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T14:00:26Z","timestamp":1784556026000},"page":"e015029","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Frontline immunotherapy with response-guided subsequent treatment (FIRST) in cutaneous squamous cell carcinoma: a Bayesian causal analysis of dose intensity, early benefit, and treatment de-escalation"],"prefix":"10.1136","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9736-9119","authenticated-orcid":false,"given":"David M","family":"Miller","sequence":"first","affiliation":[{"name":"Mass General Brigham Cancer Institute, Boston, Massachusetts, USA"},{"name":"Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA"},{"name":"Harvard Medical School, Boston, Massachusetts, USA"},{"name":"Dermatology, Massachusetts General Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross D","family":"Merkin","sequence":"additional","affiliation":[{"name":"Mass General Brigham Cancer Institute, Boston, Massachusetts, USA"},{"name":"Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA"},{"name":"Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1131-004X","authenticated-orcid":false,"given":"Howard L","family":"Kaufman","sequence":"additional","affiliation":[{"name":"Mass General Brigham Cancer Institute, Boston, Massachusetts, USA"},{"name":"Harvard Medical School, Boston, Massachusetts, USA"},{"name":"Otolaryngology, Mass Eye and Ear, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameer G","family":"Gupta","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts, USA"},{"name":"Mass Eye and Ear, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Wolkow","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts, USA"},{"name":"Department of Ophthalmology, Mass Eye and Ear, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adewunmi","family":"Adelaja","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts, USA"},{"name":"Dermatology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5344-6645","authenticated-orcid":false,"given":"Ryan J","family":"Sullivan","sequence":"additional","affiliation":[{"name":"Mass General Brigham Cancer Institute, Boston, Massachusetts, USA"},{"name":"Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA"},{"name":"Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chirayu","family":"Patel","sequence":"additional","affiliation":[{"name":"Mass General Brigham Cancer Institute, Boston, Massachusetts, USA"},{"name":"Harvard Medical School, Boston, Massachusetts, USA"},{"name":"Department of Radiation Oncology, Mass General Brigham Inc, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Sorrentino","sequence":"additional","affiliation":[{"name":"Mass General Brigham Cancer Institute, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Cohen","sequence":"additional","affiliation":[{"name":"Mass General Brigham Cancer Institute, Boston, Massachusetts, USA"},{"name":"Harvard Medical School, Boston, Massachusetts, USA"},{"name":"Surgery, Massachusetts General Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Cimoch","sequence":"additional","affiliation":[{"name":"Mass General Brigham Cancer Institute, Boston, Massachusetts, USA"},{"name":"Otolaryngology, Mass Eye and Ear, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin S","family":"Emerick","sequence":"additional","affiliation":[{"name":"Mass General Brigham Cancer Institute, Boston, Massachusetts, USA"},{"name":"Harvard Medical School, Boston, Massachusetts, USA"},{"name":"Otolaryngology, Mass Eye and Ear, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,7,20]]},"reference":[{"key":"2026072007001416000_14.7.e015029.1","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1001\/jamadermatol.2015.1187","article-title":"Incidence Estimate of Nonmelanoma Skin Cancer (Keratinocyte Carcinomas) in the U.S. Population, 2012","volume":"151","author":"Rogers","year":"2015","journal-title":"JAMA Dermatol"},{"key":"2026072007001416000_14.7.e015029.2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-0585"},{"key":"2026072007001416000_14.7.e015029.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2209813"},{"key":"2026072007001416000_14.7.e015029.4","doi-asserted-by":"crossref","first-page":"4055","DOI":"10.1038\/s41591-025-03943-w","article-title":"Neoadjuvant ipilimumab and nivolumab in resectable cutaneous squamous cell carcinoma: a randomized phase 2 trial","volume":"31","author":"Breukers","year":"2025","journal-title":"Nat Med"},{"key":"2026072007001416000_14.7.e015029.5","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.1200\/JCO-25-00387","article-title":"Response-Adapted Surgical and Radiotherapy De-Escalation in Resectable Cutaneous Squamous Cell Cancer Using Pembrolizumab: The De-Squamate Study","volume":"43","author":"Ladwa","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026072007001416000_14.7.e015029.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2502449"},{"key":"2026072007001416000_14.7.e015029.7","unstructured":"McElreath R . Rethinking: Statistical rethinking book package. 2024."},{"key":"2026072007001416000_14.7.e015029.8","doi-asserted-by":"publisher","DOI":"10.18637\/jss.v080.i01"},{"key":"2026072007001416000_14.7.e015029.9","unstructured":"Hern\u00e1n MA , Robins JM . Causal inference: what if. Chapman & Hall\/CRC, 2020."},{"key":"2026072007001416000_14.7.e015029.10","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2288-8-70","article-title":"Reducing bias through directed acyclic graphs","volume":"8","author":"Shrier","year":"2008","journal-title":"BMC Med Res Methodol"},{"key":"2026072007001416000_14.7.e015029.11","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0357-y"},{"key":"2026072007001416000_14.7.e015029.12","doi-asserted-by":"crossref","DOI":"10.1126\/science.aax0182","article-title":"Neoadjuvant checkpoint blockade for cancer immunotherapy","volume":"367","author":"Topalian","year":"2020","journal-title":"Science"},{"key":"2026072007001416000_14.7.e015029.13","doi-asserted-by":"crossref","first-page":"100759","DOI":"10.1016\/j.ejcskn.2025.100759","article-title":"Outcomes from early discontinuation of immune checkpoint inhibitor therapy following response in patients with advanced cutaneous squamous cell carcinoma","volume":"3","author":"Ladwa","year":"2025","journal-title":"EJC Skin Cancer"},{"key":"2026072007001416000_14.7.e015029.14","doi-asserted-by":"crossref","unstructured":"VanderWeele TJ . Explanation in causal inference: methods for mediation and interaction. Oxford University Press, 2015.","DOI":"10.1093\/ije\/dyw277"},{"key":"2026072007001416000_14.7.e015029.15","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/S1470-2045(23)00459-X","article-title":"Neoadjuvant cemiplimab and surgery for stage II-IV cutaneous squamous-cell carcinoma: follow-up and survival outcomes of a single-arm, multicentre, phase 2 study","volume":"24","author":"Gross","year":"2023","journal-title":"Lancet Oncol"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2026-015029","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T14:00:29Z","timestamp":1784556029000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2026-015029"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":15,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7,20]]},"published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1136\/jitc-2026-015029"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2026-015029","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]}}}